



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass

**Citation for published version:**

Petretto, E, Sarwar, R, Grieve, I, Lu, H, Kumaran, MK, Muckett, PJ, Mangion, J, Schroen, B, Benson, M, Punjabi, PP, Prasad, SK, Pennell, DJ, Kieseewetter, C, Tasheva, ES, Corpuz, LM, Webb, MD, Conrad, GW, Kurtz, TW, Kren, V, Fischer, J, Hubner, N, Pinto, YM, Pravenec, M, Aitman, TJ & Cook, SA 2008, 'Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass', *Nature Genetics*, vol. 40, no. 5, pp. 546-52. <https://doi.org/10.1038/ng.134>

**Digital Object Identifier (DOI):**

[10.1038/ng.134](https://doi.org/10.1038/ng.134)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Nature Genetics

**Publisher Rights Statement:**

Published in final edited form as:  
Nat Genet. May 2008; 40(5): 546–552.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



Published in final edited form as:

Nat Genet. 2008 May ; 40(5): 546–552. doi:10.1038/ng.134.

## Integrated genomic approaches implicate osteoglycin (*Ogn*) in the regulation of left ventricular mass

Enrico Petretto<sup>1,2,11</sup>, Rizwan Sarwar<sup>1,11</sup>, Ian Grieve<sup>1</sup>, Han Lu<sup>1</sup>, Mande K Kumaran<sup>1</sup>, Phillip J Muckett<sup>1</sup>, Jonathan Mangion<sup>1</sup>, Blanche Schroen<sup>1</sup>, Matthew Benson<sup>1</sup>, Prakash P Punjabi<sup>3</sup>, Sanjay K Prasad<sup>3</sup>, Dudley J Pennell<sup>3</sup>, Chris Kiesewetter<sup>3</sup>, Elena S Tasheva<sup>4</sup>, Lolita M Corpuz<sup>4</sup>, Megan D Webb<sup>4</sup>, Gary W Conrad<sup>4</sup>, Theodore W Kurtz<sup>5</sup>, Vladimir Kren<sup>6,7</sup>, Judith Fischer<sup>8</sup>, Norbert Hubner<sup>8</sup>, Yigal M Pinto<sup>9</sup>, Michal Pravenec<sup>6,7</sup>, Timothy J Aitman<sup>1,10</sup>, and Stuart A Cook<sup>1,3</sup>

<sup>1</sup>Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. <sup>2</sup>Division of Epidemiology, Public Health and Primary Care, Faculty of Medicine, Imperial College, Praed Street, London, W2 1PG, UK. <sup>3</sup>National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK. <sup>4</sup>Division of Biology, 116 Ackert Hall, Kansas State University, Manhattan, Kansas 66506-4901, USA. <sup>5</sup>Department of Laboratory Medicine, University of California, San Francisco, California 94143-0134, USA. <sup>6</sup>Institute of Physiology, Czech Academy of Sciences and Centre for Applied Genomics, Videňská 1083, 142 20 Prague 4, Czech Republic. <sup>7</sup>Charles University in Prague, Institute of Biology and Medical Genetics of the First Faculty of Medicine and General Teaching Hospital, Albertov 4, 128 00 Prague 2, Czech Republic. <sup>8</sup>Max-Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, Berlin-Buch, 13125, Germany. <sup>9</sup>Heart Failure Research Center, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. <sup>10</sup>Section of Molecular Genetics and Rheumatology, Division and Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0NN.

### Abstract

Left ventricular mass (LVM) and cardiac gene expression are complex traits regulated by factors both intrinsic and extrinsic to the heart. To dissect the major determinants of LVM, we combined expression quantitative trait locus1 and quantitative trait transcript2 (QTT) analyses of the cardiac transcriptome in the rat. Using these methods and *in vitro* functional assays, we identified osteoglycin (*Ogn*) as a major candidate regulator of rat LVM, with increased *Ogn* protein expression associated with elevated LVM. We also applied genome-wide QTT analysis to the human heart and observed that, out of ~22,000 transcripts, *OGN* transcript abundance had the

© 2008 Nature Publishing Group

Correspondence should be addressed to T.J.A. (t.aitman@csc.mrc.ac.uk) or S.A.C. (stuart.cook@imperial.ac.uk)..

<sup>11</sup>These authors contributed equally to this work.

#### AUTHOR CONTRIBUTIONS

The study was designed by S.A.C., E.P. and T.J.A.; S.A.C. obtained funding, supervised the study and coordinated the collaborations; R.S. performed PCR-based experiments and genotyping; H.L. and M.K.K. generated rat microarray data; B.S. and Y.M.P. generated human microarray data; M.B. generated immunofluorescence confocal micrographs; R.S. and H.L. performed cell culture and cloning experiments; R.S., B.S. and M.B. performed immunoblotting; P.J.M. and R.S. performed *in vivo* analyses in *Ogn* knockout mice; E.S.T., L.M.C., M.D.W. and G.W.C. provided and genotyped the *Ogn* knockout mice; N.H. and J.F. carried out sequence analysis of *Ogn*; T.W.K., V.K. and M.P. provided telemetric blood pressure data; P.P.P. provided human tissues for protein studies; S.K.P., D.J.P. and C.K. provided the human cardiac MRI data; E.P. designed, interpreted and supervised all statistical analyses; E.P., I.G. and R.S. performed statistical and bioinformatic analyses and were aided by J.M.; and E.P. and S.A.C. wrote the manuscript.

Note: Supplementary information is available on the Nature Genetics website.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions>

highest correlation with LVM. We further confirmed a role for *Ogn* in the *in vivo* regulation of LVM in *Ogn* knockout mice. Taken together, these data implicate *Ogn* as a key regulator of LVM in rats, mice and humans, and suggest that *Ogn* modifies the hypertrophic response to extrinsic factors such as hypertension and aortic stenosis.

Elevated indexed LVM is a major cause of morbidity and mortality and is regulated, in part, by hemodynamic indices<sup>3</sup>. However, only a small proportion of LVM variation is determined by hemodynamic effects<sup>4</sup>, and it has been proposed that genetic influences may also be important<sup>5,6</sup>. Many studies have shown that gene expression is heritable and that the genetic control of transcription affects physiological traits and disease phenotypes<sup>1,7</sup>. We have shown that gene transcription is highly heritable in the rat heart<sup>8</sup>, which led us to hypothesize that the genetic control of cardiac gene expression may be important in regulating LVM. Here, we used an integrated approach combining correlation of expression quantitative trait loci (eQTL)<sup>1</sup> and genome-wide expression profiles with physiological traits, previously designated as quantitative trait transcript (QTT) analysis<sup>2</sup>, to identify genetic determinants of LVM.

We examined regulation of LVM using the BXH/HXB panel of rat recombinant inbred (RI) strains, derived from a cross of the Brown Norway (BN) rat and the spontaneously hypertensive rat (SHR)<sup>1</sup>. We generated blood pressure telemetry data across the RI strains to assess the influence of averaged blood pressure on LVM (**Supplementary Fig. 1** online). Our data showed that LVM correlated poorly with physiological variation in blood pressure (**Supplementary Fig. 1b**). Previous studies have shown an effect of extreme pressure overload on cardiac gene expression<sup>9</sup>; however, apart from a small subset of genes (**Supplementary Table 1** online), we observed limited correlation with systolic blood pressure (SBP, median  $r = 0.14$ , 25th–75th percentiles 0.07–0.23) or diastolic blood pressure (DBP, median  $r = 0.13$ , 25th–75th percentiles 0.06–0.22). These findings are consistent with a recent study that showed limited effects of blood pressure on cardiac gene expression in three hypertensive rat strains, including the SHR<sup>10</sup>.

We then carried out eQTL analysis in the rat heart and detected 1,444 *cis* and 2,300 *trans* eQTLs at a genome-wide corrected  $P$  value ( $P_{GW}$ ) of 0.05 (**Supplementary Fig. 2a,b** online), with a predominance of *cis* eQTLs at more stringent  $P$  values (**Supplementary Fig. 2c**). Robustly mapped *cis*-regulated transcripts (false discovery rate (FDR) <5%, relative change >1.5) in the heart that colocalize with previously mapped cardiac mass or LVM QTLs represent candidate genes for these traits in the rat (**Supplementary Tables 2 and 3** online). Two of these candidate genes,  $\alpha_1\beta$ -adrenergic receptor (*Adra1b*) and thioredoxin 2 (*Txn2*), are major determinants of cardiac hypertrophy in the mouse<sup>11,12</sup>.

We next performed genome-wide QTT analysis for all eQTLs against LVM, SBP and DBP (**Supplementary Table 4** online) to identify *cis* eQTLs that correlated with LVM but not with blood pressure as primary candidate genes for the regulation of LVM. We observed the most significant QTT for a group of nine *cis*-regulated transcripts that were highly correlated with LVM and were encoded on chromosome 17p14 (Fig. 1a). Neither SBP nor DBP showed significant association with LVM by QTT analysis at this locus (Fig. 1b,c). This genomic region contains a QTL for LVM in the BXH/HXB RI strains<sup>5</sup> that we refined using additional microsatellite markers. A peak lod score of 3.98 was observed at the genetic marker *Drd1a*. Within the 2-lod support interval for this QTL (~7 cM), 113 transcripts (out of 151) reached nominal significance ( $P < 0.05$ ) of *cis* linkage (Fig. 2a,b), and 23 transcripts remained significant after Bonferroni correction for multiple testing. We prioritized *cis* eQTLs that correlated with LVM as candidate genes on the basis of the significance of their *cis* linkage and the extent of their differential expression, as previously described<sup>13</sup>. This identified two genes: the extracellular matrix (ECM) protein osteoglycin (*Ogn*;  $P = 1.9 \times$

$10^{-8}$ ) and an iron-sulfur cluster assembly-1 (*Saccharomyces cerevisiae*) homolog (*Isca1*; also known as HesB-like domain-containing 2 (*Hbld2*);  $P = 5.9 \times 10^{-7}$ ) (Fig. 2b). We then fine-mapped the LVM QTL using SNPs, which excluded *Hbld2* as a positional candidate (Supplementary Table 5 online). These analyses prioritized *Ogn* as the only *cis*-regulated transcript that was both highly differentially regulated and correlated with LVM, but they do not exclude influences from other genes within the refined QTL interval. Sequence analysis of *Ogn* revealed several SNPs and a 47-bp indel in the 3' UTR of the gene (Fig. 2c).

Subsequently, we used primary cultures of neonatal cardiac myocytes to examine the regulation of *Ogn* in response to hypertrophic stimulation by phenylephrine; this is an established and blood pressure-independent *in vitro* model of cardiac myocyte hypertrophy<sup>14</sup>. During the course of the hypertrophic response, *Ogn* transcript levels were significantly downregulated (Fig. 2d). As expected, natriuretic peptide precursor A (*Nppa*), a biomarker of cardiac hypertrophy, was upregulated in the model<sup>14</sup> (Supplementary Fig. 3a online). *Adra1b* and *Txn2* (Supplementary Fig. 3b,c), established determinants of LVM in the mouse<sup>11,12</sup> and candidate genes in the rat (Supplementary Table 2), showed dynamic regulation similar to that observed for *Ogn*. These eQTL, QTT and *in vitro* results, taken together with recent finding that ECM proteins are critical determinants of cardiac hypertrophy<sup>15,16</sup>, prioritize *Ogn* as a strong positional and biological candidate for LVM in the rat.

To translate our findings to humans, we generated genome-wide expression profiles of the human heart using biopsies collected from 20 individuals with aortic stenosis and elevated LVM and from seven control subjects. From this cohort, we selected subjects at the extremes of the distribution of LVM (see Methods) to identify genes that show strong differential regulation between individuals with high and low LVM. Differentially regulated genes (FDR = 5%, relative change >1.5) that correlated most highly with LVM across the study population are reported in Table 1. Notably, out of the 22,284 transcripts considered, *OGN*, the human ortholog of rat *Ogn*, correlated most strongly with LVM, and this correlation remained significant after controlling for the presence or absence of aortic stenosis ( $r = 0.45$ ,  $P = 0.02$ ). *NPPA* and natriuretic peptide precursor B (*NPPB*), biomarkers of cardiac hypertrophy, were upregulated in individuals with aortic stenosis (aortic stenosis versus controls; relative change = 2.6,  $P = 0.006$  and relative change = 9.5,  $P = 0.01$ , respectively); however, unlike *OGN*, they did not significantly correlate with LVM when the test was made conditional on aortic stenosis status. We then analyzed two more published microarray datasets and independently replicated the association of *OGN* with increased LVM and markers of hypertrophy in these cohorts (Supplementary Table 6 online).

In our cohort of all subjects considered for the biopsy studies, we observed a weak correlation of LVM with peak velocity across the aortic valve ( $V_{\max}$ ; Fig. 3a) and aortic valve area index (AVAI; Fig. 3b), established clinical measures of aortic stenosis severity<sup>17</sup>. However, as calculation of LVM by echocardiography relies on assumptions of left ventricular geometry, we studied an independent cohort of subjects with aortic stenosis in which LVM,  $V_{\max}$  and AVAI were assessed by cardiac MRI. This confirmed limited effects of pressure indices on variation in LVM (Fig. 3c,d). Our data suggest that the severity of aortic valve narrowing, the major extrinsic stimulus for LVM in patients with aortic stenosis, determines only a limited amount of LVM variation.

On review of the association of *Ogn* expression with LVM, we observed an apparent inconsistency in the direction of the correlation between species ( $r = -0.46$ , rat;  $r = 0.62$ , human). However, differential expression, as determined by microarrays, can reflect sequence variation or alternative splicing in the 3' UTR<sup>18</sup>. Further analysis revealed that, of

four microarray probe sets for rat *Ogn*, two mapped as cis eQTLs and correlated with LVM variation, whereas two did not (**Supplementary Fig. 4** online), suggestive of alternative splicing in the 3' UTR, which was confirmed by RT-PCR (Fig. 4a). This alternative splicing resulted in two isoforms of the 3' UTR: a short isoform (~106 bp) that was more abundant in the BN strain and a long isoform (~1,560 bp) that was more abundant in the SHR strain (Fig. 4b). The allelic effect of the 47-bp sequence polymorphism (Fig. 2c) on the abundance of the 3' UTR isoforms was confirmed across the RI strains ( $P < 10^{-11}$  for both isoforms; Fig. 4c). By luciferase assay, the short isoform was more efficient for protein production than the long isoform (Fig. 4d), and there was three times the expression of *Ogn* protein in BN heart as in SHR heart (Fig. 4e,f). To determine the cell types expressing *Ogn* in the heart, we examined primary cultures of neonatal cardiac myocytes and cardiac fibroblasts, which revealed equivalent *Ogn* protein expression in these cell types, with greater secretion of *Ogn* by fibroblasts (**Supplementary Fig. 5** online). We confirmed expression of *Ogn* in isolated adult rat cardiac myocytes by confocal microscopy, which revealed association of *Ogn* with the sarcomere (Fig. 4g).

Our data showed that the BN genotype at chromosome 17p14, associated with the 47-bp insertion, accounted for a considerable amount (47%) of LVM variation in the RI strains; factors explaining the remaining phenotypic variation are unknown. As the *Ogn* sequence variant is associated with high LVM, independently of blood pressure, and correlates with increased *Ogn* protein expression (Fig. 4e,f), we suggest that the 47-bp insertion, present in the BN and other strains (**Supplementary Figs. 4, 6 and 7** online), promotes splicing of the *Ogn* 3' UTR, and that the greater abundance of the short isoform in the BN results in higher amounts of *Ogn* protein. We further determined the *Ogn* 3' UTR indel across 30 rat strains, selected for protein studies four strains with the insertion and five strains without and confirmed the association of the insertion with increased *Ogn* ( $P = 0.008$ ) (**Supplementary Fig. 7**).

The association of *Ogn* transcript abundance with LVM in rats and humans led us to hypothesize that *Ogn* protein expression might be central to hypertrophic response irrespective of the stimulus, which could be physiological or pathophysiological. To examine this, we studied an independent cohort of individuals with concentric hypertrophy secondary to aortic stenosis or hypertensive heart disease or eccentric hypertrophy secondary to ischemic heart failure (**Supplementary Table 7** online). We observed that high amounts of *OGN* protein were associated with elevated LVM (Spearman's correlation = 0.7,  $P = 0.019$ ) whereas neither SBP (Spearman's correlation = 0.1,  $P = 0.4$ ) nor DBP (Spearman's correlation = 0.02,  $P = 0.5$ ) correlated with *OGN* protein (**Supplementary Table 7** and **Supplementary Fig. 8** online).

To validate functionally the role of *Ogn* in the *in vivo* regulation of LVM, we studied *Ogn* knockout (*Ogn*<sup>-/-</sup>) mice<sup>19</sup>. Although we observed no difference in LVM in *Ogn*<sup>-/-</sup> mice as compared to controls at baseline (Fig. 5a), it is established that permissive physiological perturbations are frequently required to reveal cardiovascular phenotypes in knockout mice<sup>9,20</sup>. Therefore, we used subcutaneous angiotensin II infusion as a pro-hypertrophic stimulus and observed that *Ogn*<sup>+/-</sup> and *Ogn*<sup>-/-</sup> mice showed a significant attenuation ( $P = 0.002$  and  $P = 0.02$ , respectively) in LVM response as compared to *Ogn*<sup>+/+</sup> controls. We then determined the expression of *Nppa*, *Nppb* and  $\alpha$ -skeletal smooth muscle actin (*Acta1*, a structural cellular marker of hypertrophy). This showed a significant reduction in *Acta1* ( $P = 0.02$ ) in the *Ogn*<sup>-/-</sup> mice after angiotensin II infusion (**Supplementary Table 8** online), in keeping with the effects of other ECM proteins on the hypertrophic response<sup>21</sup>. Although there was no difference in SBP or DBP between the *Ogn*<sup>+/+</sup> controls and either *Ogn*<sup>+/-</sup> or *Ogn*<sup>-/-</sup> mice at baseline, we observed a significant increase in DBP in the *Ogn*<sup>-/-</sup> mice during angiotensin II infusion (Fig. 5b). The effect of *Ogn* on LVM remained apparent



despite the *Ogn*<sup>-/-</sup> mice having a higher blood pressure, which may be due to noncardiac effects of *Ogn* deletion.

In summary, our data implicate *Ogn* as an important regulator of LVM in rats, mice and humans. Our data show that sequence variation in the *Ogn* 3' UTR in the rat, which has multiple forms in other species<sup>22</sup>, is associated with increased *Ogn* protein expression and elevated LVM. The ENCYClopedia Of Dna Elements (ENCODE) pilot project highlighted an enrichment in indel rates in 3' UTRs, and alternative 3' UTR splicing contributes to disease severity and susceptibility<sup>18,23</sup>. We suggest that, in addition to modifying disease, 3' UTR variation may also account for phenotypic variation in physiological traits. *Ogn* is an ECM protein and a member of the small leucine-rich repeat protein family<sup>19,24</sup>. ECM proteins are increasingly recognized as major determinants of the hypertrophic response acting, in part, through modulation of the transforming growth factor beta (TGF- $\beta$ ) signaling pathway<sup>15,16</sup>. Furthermore, mouse studies have shown that the TGF- $\beta$  signaling is important for cardiac hypertrophy secondary to aortic banding<sup>25</sup>. Therefore, we speculate that *Ogn* may influence LVM through modulation of the TGF- $\beta$  pathway. A role for the TGF- $\beta$  signaling pathway in the regulation of LVM is supported by our data that show an association of LVM in humans with several important genes in this pathway (*ASPN*, *FBN1*, *FSTL1*, *LTBP*, *TUBA1B* and *TUBA1C*) (Table 1). In conclusion, we propose that variation of LVM is explained by the interplay of genetic factors<sup>6</sup> and hemodynamic components other than conventional measures of blood pressures or aortic stenosis<sup>26</sup>. Discovery of genes, such as *Ogn*, and pathways that intrinsically regulate LVM may help identify new approaches for treating human heart disease.

## METHODS

### Rats and mice

The BXH/HXB RI strain panel has been described in detail elsewhere<sup>1,5</sup>. We determined indexed LVM by averaging measurements of LVM corrected for body weight in four to six male rats within each RI strain<sup>5</sup>. For microarray studies, we collected hearts from four males of each RI strain and five from each parental strain; the apex of the left ventricle was isolated and frozen in liquid nitrogen. Immunoblotting was performed using 8-week-old male BN and SHR males (Charles River). *Ogn*<sup>-/-</sup> mice were made as previously described<sup>19</sup> and backcrossed to C57BL/6 for more than 10 generations. Details of the 27 other rat strains used are given in **Supplementary Table 9** online. We studied male mice between 9 and 17 weeks old in age-matched groups. All animal procedures were performed under license from the UK Home Office or in accordance with the Animal Protection Law of the Czech Republic.

### Blood pressure measurements

In the rat studies, we implanted indwelling aortic radiotelemetry transducers (Data Sciences International) at 8 weeks of age and measured arterial pressure in conscious, unrestrained rats. Radiotelemetry pressure was collected in 5-s bursts every 10 min and recorded over a period of 8 d, using 6–12 rats within each RI strain. For studies in mice, we measured tail cuff blood pressures in conscious mice that were preacclimatized to experimental conditions for 2 weeks. Blood pressure values were averaged within each RI strains and across eight sequential readings, three times per week (2 weeks before and after pump insertion).

### Microarray data

RNA was extracted from heart samples and prepared for microarray analysis as previously described<sup>1</sup>. We used the Affymetrix RAE 230 2.0 and the Affymetrix U133A microarrays for rat and human studies, respectively. Gene expression summary values for Affymetrix

GeneChip data were computed using the Robust Multichip Average (RMA) algorithm as described<sup>1</sup>. Relative changes were determined by RMA values, backtransformed (anti-log<sub>2</sub>) to raw intensity scale.

### Expression QTL mapping

For each transcript on the microarray, eQTL linkages and false discovery rate (FDR) at a given genome-wide significance level ( $P_{GW}$ ) were determined as previously described<sup>1</sup>. We determined which eQTLs were regulated in *cis* or in *trans* by defining *cis* eQTLs as those with a peak of linkage within 10 Mbp of the physical location of the probe set<sup>1</sup>. To avoid misclassification of *cis* and *trans* eQTLs, probe sets whose physical position mapped to more than one place in the genome were removed from the dataset<sup>8</sup>.

### Quantitative trait transcript analysis

We assessed association between gene expression levels and phenotypic variation across the population by correlating transcript abundance with the values of physiological traits<sup>2</sup>. Pearson correlation coefficients ( $r$ ) and Westfall-Young corrected  $P$  values based on 10,000 permutations were calculated using Matlab version 6 (**Supplementary Table 4**).

### QTL mapping of LVM

We performed linkage analysis of LVM data in MapManager QTXb20 using the expanded 1,011 marker set<sup>1</sup> with another 17 fluorescently labeled microsatellite markers within the region of interest on rat chromosome 17p14 (**Supplementary Table 10** online). Amplification products of microsatellite markers across the RI strain panel were detected on a 3730xl DNA Analyzer (Applied Biosystems) and genotype data analyzed using GeneMapper version 3.7 (Applied Biosystems). To refine the boundaries of the LVM QTL on rat chromosome 17p14, we carried out fine mapping of LVM using 46 informative SNPs within the QTL region. SNPs were retrieved from the STAR project consortium (see URLs below).

### RT-PCR of *Ogn* 3' UTR

RNA was quantified by a standard curve (RiboGreen, Invitrogen), treated with DNase I (Invitrogen) and used to make cDNA with AMV reverse transcriptase (Roche). After cDNA clean up (MicroSpin G-50 columns, Amersham), we carried out PCR with KOD Hot Start DNA Polymerase (Novagen). PCR conditions were 95 °C (12 min), then 30 cycles of 95 °C, 30 s; 62 °C, 30 s. PCR products were visualized on a 1.5% agarose gel with ethidium bromide. Primer pairs are given in **Supplementary Methods** online.

### Quantitative RT-PCR

We used the One-Step TaqMan RT-PCR Master Mix (Applied Biosystems) with normalization to total RNA as previously described<sup>1</sup>. Quantification of the *Ogn* 3' UTR variants and assays of mouse left ventricle were performed by two-step quantitative RT-PCR (iScript cDNA Synthesis, Bio-Rad; SYBR Green I JumpStart Taq Readymix, Sigma) as per manufacturer's instructions. Primers pairs and PCR conditions are given in **Supplementary Methods**.

### Immunoblotting and immunohistochemistry

Protein extracts from heart samples were prepared and analyzed by SDS-PAGE and immunoblotting as previously described<sup>27</sup>. Antibodies to mouse *Ogn* were from R&D Systems (goat, AF2949); those to human *Ogn* were from Chemicon (rabbit, AB2210), and secondary antibodies were from R&D or Dako, respectively. After immunoblotting, equal

loading was confirmed using Ponceau S solution (Sigma). Proteins were quantified with Quantity One software (Bio-Rad). For immunohistochemistry, adult cardiac myocytes were isolated, stained and imaged as described in the **Supplementary Methods**.

### Cloning and luciferase assay

The 3' UTR of *Ogn* was amplified by PCR from BN and SHR heart cDNA (conditions as above). PCR products were gel-purified and TA cloned into pTargetT (Promega). Sequence-verified BN and SHR *Ogn* 3' UTRs were subcloned to psiCHECK-2 (Promega). For luciferase assays, we seeded COS-1 cells in 24-well dishes at a density of  $10^5$  cells per well and transfected them with 100 ng of psiCHECK-2-*Ogn* 3' UTR using Lipofectamine 2000. Cells were collected after 24 h and *Renilla* and firefly luciferase activity detected using Dual-Glo Luciferase (Promega).

### Neonatal rat cardiac myocytes and cardiac fibroblast cultures

We prepared primary cultures of neonatal rat ventricular cardiac myocytes as previously described<sup>27</sup>. After serum starvation (24 h), cells were stimulated with phenylephrine (100  $\mu$ M) and RNA extracted (RNeasy, Qiagen) at the specified time-points. For cultures of cardiac fibroblasts, cells were seeded on 60-mm plates during purification of neonatal rat ventricular myocytes. Fibroblasts were grown to confluence and passaged using standard approaches and culture conditions as used for cardiac myocytes. Cells were used for experiments at the third passage.

### Human myocardial biopsies for microarray and protein studies

We obtained cardiac needle biopsies specimens from 20 individuals with aortic stenosis undergoing valve replacement surgery, selected from an extended study group of 45 characterized by echocardiography, and from seven sex-matched subjects without aortic stenosis at the time of coronary bypass grafting as previously described<sup>28</sup> (further details are given in **Supplementary Methods**). LVM and aortic valve area index (AVAI) were calculated using standard echocardiography techniques and normalized to body mass index<sup>17</sup>. For differential expression analysis, two groups were selected on the basis of their LVM: individuals with low LVM ( $93 \text{ g/m}^2$ ,  $n = 7$ ) and individuals with high LVM ( $142 \text{ g/m}^2$ ,  $n = 7$ ). The cut-offs were the 25th and 75th percentiles of the LVM distribution, respectively. The local Ethics Committee of the University Hospital Maastricht approved the study.

For protein studies, we used a distinct cohort of eight subjects; details are given **Supplementary Table 7**. Full-thickness myocardial biopsies were taken at the time of cardiac surgery with the approval of the Hammersmith Hospital Research Ethics Committee. We obtained written informed consent from all subjects.

### Cardiac MRI study

Individuals with a diagnosis of aortic stenosis who attended the Royal Brompton Hospital, London cardiac MRI unit between 2002 and 2007 were retrospectively identified from a local database with the approval of the hospital Research Ethics Committee. This identified 474 people with a diagnosis of aortic stenosis. Of this cohort, 123 had isolated aortic stenosis in the absence of confounding cardiac valve or myocardial pathology and were used for the study. The mean age of the subjects was 61.7 years (range 9–89), with 64% males and 36% females. We acquired MRI cine images, aortic blood flow velocities and gadolinium-DTPA contrast-enhanced images (1.5 Tesla, Siemens Sonata). LVM, left ventricular ejection fraction and aortic valve area planimetry, from which LVM and AVAI were calculated, were determined using standard approaches<sup>29</sup>.



## Angiotensin II infusion studies

We implanted osmotic pumps (1002, Alzet) subcutaneously under general anesthesia. AII was infused (1.5 µg/g/day) for 2 weeks, while mice were housed under standard conditions. After the infusion period, mice were weighed, hearts were collected and the left ventricle was isolated by removal of the great vessels, atria and the right ventricle; it was then rinsed and blotted dry. LVMs (expressed as a percentage of body mass) of *Ogn*<sup>-/-</sup> mice were compared to those of littermate or wild-type *Ogn*<sup>+/+</sup> mice and those of littermate *Ogn*<sup>+/-</sup> mice. Data were collected in single-blinded fashion.

## Statistical analysis

Data are presented as mean ± s.e.m. and were compared using a Student's *t*-test (or Mann-Whitney *U*-test, as appropriate) or repeated-measures, one-way analysis of variance followed by Dunnett's *post hoc* test. We analyzed differential expression in the human microarray data using Statistical Analysis of Microarrays (SAM) and used 10,000 permutations to estimate the false discovery rate<sup>30</sup>. Multivariate regression analysis was carried out to evaluate the effect of indices of disease severity ( $V_{\max}$ , peak velocity of aortic blood flow and AVAI) on LVM in the cohorts of individuals with aortic stenosis. We built regression models by adding all significant covariates ( $P < 0.05$ ), including sex, age and ejection fraction, and calculated the unique contributions ( $R^2$  values) of  $V_{\max}$  and AVAI to variation of LVM. Calculations were done with SPSS 12.0.

## URLs

STAR project consortium, <http://www.snp-star.eu/>.

## Accession codes

ArrayExpress: rat microarray data have been deposited under experiment number E-MIMR-222. NCBI GEO: human expression data have been deposited with accession code GSE10161.

## Acknowledgments


Mice used in this study were produced by Eli Lilly, Inc., and made available to the authors. We are grateful to R. Buchan for technical assistance, to P. Froguel, A. Angius, M. Falchi and M. Schneider for comments on the manuscript, to S. Harding (National Heart and Lung Institute, Imperial College, London) for providing the isolated adult rat cardiac myocytes and to J. Sassard (University of Lyon) for providing DNA from the Lyon rat strains. This work was primarily supported by funding from the UK Department of Health (S.A.C. and H.L.) and the British Heart Foundation (R.S., S.A.C.). In addition, studies were supported by research grants from the Medical Research Council of UK (T.J.A., S.A.C.), the Fondation Leducq (T.J.A., S.A.C., M.B.), the EU EURATools award (T.J.A., S.A.C., N.H., M.P.), the Wellcome Trust (I.G.), the Howard Hughes Medical Institute Research Scholars Program (M.P.), the Grant Agency of the Czech Republic (M.P.), the Ministry of Education of the Czech Republic (M.P., V.K.), the 2003T302 grant of the Netherlands Heart Foundation (Y.M.P.), the InterCardiology Institute Netherlands (Y.M.P.), a Rubicon grant from the Netherlands Organisation for Scientific Research (NWO, to B.S.), the Wellcome Trust Functional Genomics Initiative and the Biological Atlas of Insulin Resistance (BAIR) (M.K.K.), the German National Genome Research Network (NGFN2, to N.H.), and the US National Institutes of Health's National Eye Institute EY000952 and EY13395 (G.W.C.).

## References

- Hubner N, et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. *Nat. Genet.* 2005; 37:243–253. [PubMed: 15711544]
- Passador-Gurgel G, Hsieh WP, Hunt P, Deighton N, Gibson G. Quantitative trait transcripts for nicotine resistance in *Drosophila melanogaster*. *Nat. Genet.* 2007; 39:264–268. [PubMed: 17237783]
- Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation.* 2000; 102:470–479. [PubMed: 10908222]


4. Devereux RB, et al. Relations of left ventricular mass to demographic and hemo-dynamic variables in American Indians: The Strong Heart Study. *Circulation*. 1997; 96:1416–1423. [PubMed: 9315526]
5. Pravenec M, et al. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. *J. Clin. Invest.* 1995; 96:1973–1978. [PubMed: 7560090]
6. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. *Hypertension*. 1997; 30:1025–1028. [PubMed: 9369250]
7. de Koning DJ, Haley CS. Genetical genomics in humans and model organisms. *Trends Genet.* 2005; 21:377–381. [PubMed: 15908034]
8. Petretto E, et al. Heritability and tissue specificity of expression quantitative trait loci. *PLoS Genet.* 2006; 2:e172. [PubMed: 17054398]
9. Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. *J. Clin. Invest.* 2002; 109:849–855. [PubMed: 11927610]
10. Cerutti C, et al. Transcriptional alterations in the left ventricle of three hypertensive rat models. *Physiol. Genomics*. 2006; 27:295–308. [PubMed: 16882881]
11. Yoshioka J, et al. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. *Circulation*. 2004; 109:2581–2586. [PubMed: 15123525]
12. O'Connell TD, et al. The  $\alpha(1A/C)$ - and  $\alpha(1B)$ -adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. *J. Clin. Invest.* 2003; 111:1783–1791. [PubMed: 12782680]
13. Goring HH, et al. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. *Nat. Genet.* 2007; 39:1208–1216. [PubMed: 17873875]
14. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. *Circulation*. 2003; 108:664–667. [PubMed: 12900338]
15. Oka T, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. *Circ. Res.* 2007; 101:313–321. [PubMed: 17569887]
16. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. *J. Clin. Invest.* 2007; 117:568–575. [PubMed: 17332884]
17. Cheitlin MD, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography. *J. Am. Soc. Echocardiogr.* 2003; 16:1091–1110. [PubMed: 14566308]
18. Birney E, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature*. 2007; 447:799–816. [PubMed: 17571346]
19. Tasheva ES, et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. *Mol. Vis.* 2002; 8:407–415. [PubMed: 12432342]
20. Hirota H, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. *Cell*. 1999; 97:189–198. [PubMed: 10219240]
21. Schroen B, et al. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. *J. Exp. Med.* 2007; 204:1227–1235. [PubMed: 17485520]
22. Tasheva ES, Corpuz LM, Funderburgh JL, Conrad GW. Differential splicing and alternative polyadenylation generate multiple mimecan mRNA transcripts. *J. Biol. Chem.* 1997; 272:32551–32556. [PubMed: 9405469]
23. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. *Nat. Rev. Genet.* 2007; 8:749–761. [PubMed: 17726481]
24. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. *J. Cell. Physiol.* 2001; 189:266–274. [PubMed: 11748584]
25. Zhang D, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. *Nat. Med.* 2000; 6:556–563. [PubMed: 10802712]
26. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. *Am. J. Hypertens.* 2007; 20:378–384. [PubMed: 17386343]

27. Cook SA, Sugden PH, Clerk A. Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. *Circ. Res.* 1999; 85:940–949. [PubMed: 10559141]
28. Schroen B, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. *Circ. Res.* 2004; 95:515–522. [PubMed: 15284191]
29. Caruthers SD, et al. Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis: comparison with echocardiography. *Circulation.* 2003; 108:2236–2243. [PubMed: 14568899]
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. USA.* 2001; 98:5116–5121. [PubMed: 11309499]




**Figure 1.**

Quantitative trait transcripts analysis of *cis* eQTLs with physiological traits in the rat. Expression profiles of the 1,444 *cis* eQTLs ( $P_{\text{GW}} = 0.05$ ) were correlated with values of (a) indexed LVM, (b) DBP and (c) SBP measured in the BXH/HXB RI strain panel. For each *cis* eQTL across the rat genome, the absolute Pearson correlation coefficient with the physiological traits is plotted against the location of the probe set (Mb). Vertical lines, physical position of the end of each rat chromosome. The number of each chromosome is given on the upper y axis. The horizontal lines indicate empirical significance levels  $P = 0.05$ ,  $P = 0.01$  and  $P = 0.001$  of the correlations (see Methods).


**Figure 2.**

Candidate *cis*-regulated genes within the rat QTL for left ventricular mass. **(a)** Interval mapping of LVM to chromosome 17p14 in the BXH/HXB RI strain panel. Horizontal dashed line, genome-wide threshold for significance ( $P = 0.05$ ) of linkage derived by 10,000 permutations; 2-*lod* support interval region, by vertical box (dotted lines). Positions of the genetic markers are also indicated along the x axis. **(b)** Volcano plot of significance of *cis* eQTLs against their relative change in expression. Circles represent 113 transcripts physically encoded within the 2-*lod* support interval of the QTL and showing *cis* linkage at their nearest markers (nominal  $P < 0.05$ , two-tailed Mann-Whitney  $U$ -test). For each transcript, the negative  $\log_{10}$  of the  $P$  value of linkage is plotted against the relative change in gene expression at the peak of linkage. Dashed horizontal line, significance threshold ( $P = 0.00033$ ) after Bonferroni correction for multiple testing owing to the number of transcripts in the region that were tested for *cis* linkage. Transcripts representing *Hbld2* (one probe set) and *Ogn* (two probe sets) are indicated by the arrows. **(c)** Sequence polymorphisms in *Ogn* genomic DNA from 2 kb upstream of the first exon to 3 kb downstream of the stop codon. For 5' UTR, exonic and 3' UTR variants, positions are reported relative to the start codon; for intronic variants, positions are given relative to the nearest exon. The sequences variation at position 348 in exon 3 of *Ogn* is synonymous. Ins, insertion. **(d)** Regulation of *Ogn* in a blood pressure-independent *in vitro* model of cardiac myocyte hypertrophy: neonatal rat ventricular myocytes stimulated with phenylephrine for the times shown and assayed by quantitative RT-PCR for changes in *Ogn* mRNA expression. Mean relative change ( $\pm$  s.e.m.) in gene expression as compared to control samples over the time course of the experiment; \* $P < 0.05$ , \*\* $P < 0.01$ .






**Figure 3.** Correlation between hemodynamic indices and indexed LVM in individuals with aortic stenosis. **(a–d)** We observed little correlation between LVM and peak velocity across the aortic valve ( $V_{max}$ ) or indexed aortic valve area (AVAI), indices of aortic stenosis severity and hemodynamic pressure, in two independent cohorts of subjects with aortic stenosis characterized by echocardiography **(a,b,  $n = 45$ )** or cardiac MRI **(c,d,  $n = 123$ )**, respectively. The percentage of variance of LVM accounted for by hemodynamic indices after including all significant covariates ( $R^2$ ) is indicated.



**Figure 4.**

Molecular characterization of rat *Ogn*. (a) PCR products of *Ogn* 3' UTR generated from BN and SHR cDNA, showing the presence of two splice variants. (b) Abundance of the 3' UTR isoforms and total coding mRNA in the parental strains. Each data point represents the relative expression in one BN (circle) or one SHR (triangle) rat of total coding, short and long isoforms of *Ogn*. \* $P < 0.01$ , \*\* $P < 0.001$ . (c) Abundance of the 3' UTR isoforms and total coding mRNA in the RI strains. Each data point represents relative *Ogn* expression in one rat from each of the RI strains carrying either the BN (circle) or SHR (triangle) allele; \*\* $P < 10^{-11}$ . (d) Effects of the BN and SHR 3' UTR isoforms on protein synthesis as determined by luciferase assay. Isoforms: BN long, BN-L; BN short, BN-S; SHR long SHR-L; SHR short, SHR-S. \*\* $P < 0.0001$ . (e) Immunoblot of Ogn protein expression in 20  $\mu$ g total protein from three BN and three SHR hearts. Immature pre-Ogn, ~50 kDa, mature Ogn protein, ~20 kDa. (f) Semiquantitative densitometry of data shown in e. \*\* $P < 0.0001$ . (g) Immunofluorescence confocal micrographs of isolated adult rat ventricular cardiac myocytes. Top left, sarcomeric proteins labeled with rhodamine-conjugated phalloidin; top right, DAPI counterstain of nuclei; bottom left, Ogn protein detected using antibodies to Ogn and a secondary antibody labeled with Alexa Fluor 488; bottom right, merged image. Mean  $\pm$  s.e.m. (d,f); NS, not significant.



**Figure 5.**

*In vivo* regulation of LVM in *Ogn* knockout mice. **(a)** Indexed LVM in mice at baseline and after hypertrophic stimulation by angiotensin II infusion over a 2-week period ( $n = 14$ – $18$  for  $Ogn^{+/+}$ ,  $n = 6$ – $10$  for  $Ogn^{+/-}$  or  $Ogn^{-/-}$ ). **(b)** SBP and DBP in mice at baseline and after angiotensin II infusion ( $n = 6$  for  $Ogn^{+/+}$ ,  $n = 3$ – $5$  for  $Ogn^{+/-}$  or  $Ogn^{-/-}$ ). All results are given as mean  $\pm$  s.e.m. *P* values were generated by one-way analysis of variance with the Dunnett's *post hoc* test for multiple comparisons using the wild-type mice ( $Ogn^{+/+}$ ) as the reference group. \* $P < 0.05$ ; \*\* $P = 0.002$ ; NS, not significant.

**Table 1**  
Differentially expressed genes in human cardiac hypertrophy and associated with indexed left ventricular mass

Probe identifier	Gene symbol	Gene name	Relative change <sup>a</sup>	FDR <sup>b</sup> (%)	Correlation with LVM <sup>c</sup>	P value <sup>d</sup>
218730_s_at	<i>OGN</i>	Osteoglycin	2.2	2.7	0.62	$1.2 \times 10^{-3}$
202766_s_at	<i>FBN1</i>	Fibrillin 1	2.0	2.7	0.55	$4.5 \times 10^{-3}$
209621_s_at	<i>PDLIM3</i>	PDZ and LIM domain 3	1.6	5.0	0.52	$6.5 \times 10^{-3}$
219087_at	<i>ASPN</i>	Asporin	1.9	5.0	0.52	$7.5 \times 10^{-3}$
213646_x_at	<i>TUBA1B</i>	Tubulin, alpha 1b	1.5	2.7	0.52	$5.7 \times 10^{-3}$
213765_at	<i>MFAP5</i>	Microfibrillar associated protein 5	1.8	5.0	0.51	$6.8 \times 10^{-3}$
203570_at	<i>LOXLI</i>	Lysyl oxidase-like 1	1.5	5.0	0.51	$8.1 \times 10^{-3}$
208782_at	<i>FSTL1</i>	Follistatin-like 1	1.5	2.7	0.51	$1.1 \times 10^{-2}$
213867_x_at	<i>ACTB</i>	Actin, beta	1.5	2.7	0.49	$1.1 \times 10^{-2}$
212614_at	<i>ARID5B</i>	AT rich interactive domain 5B	1.6	2.7	0.49	$9.9 \times 10^{-3}$
216442_x_at	<i>FN1</i>	Fibronectin 1	1.9	5.0	0.49	$1.1 \times 10^{-2}$
211750_x_at	<i>TUBA1C</i>	Tubulin, alpha 1c	1.6	2.7	0.48	$1.3 \times 10^{-2}$
212582_at	<i>OSBPL8</i>	Oxysterol binding protein-like 8	1.6	2.7	0.48	$1.1 \times 10^{-2}$
221729_at	<i>COL5A2</i>	Collagen, type V, alpha 2	1.9	5.0	0.48	$1.3 \times 10^{-2}$
201843_s_at	<i>EFEMP1</i>	EGF- fibulin-like extracellular matrix protein 1	1.8	5.0	0.48	$1.2 \times 10^{-2}$
202007_at	<i>NID1</i>	Nidogen 1	1.6	2.7	0.47	$1.6 \times 10^{-2}$
203548_s_at	<i>LPL</i>	Lipoprotein lipase	1.8	2.7	0.47	$1.7 \times 10^{-2}$
205547_s_at	<i>TAGLN</i>	Transgelin	2.1	2.7	0.46	$1.7 \times 10^{-2}$
202552_s_at	<i>CRML1</i>	Cysteine rich transmembrane BMP regulator 1	1.6	3.9	0.46	$1.9 \times 10^{-2}$
201012_at	<i>ANXA1</i>	Annexin A1	1.6	2.7	0.46	$1.7 \times 10^{-2}$
209460_at	<i>ABAT</i>	4-aminobutyrate aminotransferase	1.6	2.7	0.45	$2.0 \times 10^{-2}$
201302_at	<i>ANXA4</i>	Annexin A4	1.5	3.9	0.44	$2.1 \times 10^{-2}$
219260_s_at	<i>C17orf81</i>	Chromosome 17 open reading frame 81	1.5	2.7	0.44	$2.4 \times 10^{-2}$
209130_at	<i>SNAP23</i>	Synaptosomal-associated protein, 23kda	1.5	5.0	0.44	$2.6 \times 10^{-2}$
209392_at	<i>ENPP2</i>	Ectonucleotide pyrophosphatase/phosphodiesterase 2	1.6	2.7	0.43	$2.7 \times 10^{-2}$
200974_at	<i>ACTA2</i>	Actin, alpha 2, smooth muscle, aorta	1.6	2.7	0.43	$2.8 \times 10^{-2}$

Probe identifier	Gene symbol	Gene name	Relative change <sup>a</sup>	FDR <sup>b</sup> (%)	Correlation with LVM <sup>c</sup>	P value <sup>d</sup>
210942_s_at	<i>ST3GAL6</i>	ST3 beta-galactoside alpha-2,3-sialyltransferase 6	1.5	5.0	0.42	$3.3 \times 10^{-2}$
212063_at	<i>CD44</i>	CD44 molecule	1.9	3.9	0.42	$3.0 \times 10^{-2}$
212515_s_at	<i>DDX3X</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked	1.5	5.0	0.41	$3.6 \times 10^{-2}$
211509_s_at	<i>RTN4</i>	Reticulon 4	1.6	3.9	0.41	$3.7 \times 10^{-2}$
209387_s_at	<i>TM4SF1</i>	Transmembrane 4 L six family member 1	1.8	2.7	0.40	$4.0 \times 10^{-2}$
219922_s_at	<i>LTBP3</i>	Latent transforming growth factor beta binding protein 3	1.5	5.0	0.40	$4.3 \times 10^{-2}$
202119_s_at	<i>CPNE3</i>	Copine III	1.5	3.9	0.40	$4.8 \times 10^{-2}$
210095_s_at	<i>IGFBP3</i>	Insulin-like growth factor binding protein 3	1.7	2.7	0.39	$5.0 \times 10^{-2}$

<sup>a</sup>Relative change in expression between subjects with low ( 93 g/m<sup>2</sup>) and high ( 142 g/m<sup>2</sup>) LVM in the study population.

<sup>b</sup>False discovery rate for differential expression, estimated by SAM analysis.

<sup>c</sup>Data are ranked according to decreasing values of the Pearson correlation with LVM (determined noninvasively by echocardiography).

<sup>d</sup>Empirical P values for the correlations were calculated by 10,000 permutations.